ArticleJournal of cancer research and clinical oncology2025
DHRS9 promotes malignant progression of ovarian cancer through SQSTM1.
Article in Journal of cancer research and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis research explores the prognostic value of DHRS9 in ovarian carcinoma and elucidates its regulatory mechanisms.
methodsBioinformatic analyses were applied to clarify the association between DHRS9 expression level and clinical survival outcomes in ovarian cancer patients. Functional assays were conducted to evaluate cell growth, migration, and invasion. Apoptosis was quantified via flow cytometry. The expression of Dehydrogenase/Reductase Member 9 (DHRS9) and sequestosome 1 (SQSTM1) at both mRNA and protein levels was analyzed via quantitative real-time polymerase chain reaction (qRT-PCR) and western blot assays. Mass spectrometry identified SQSTM1 as a putative downstream effector of DHRS9, and their interaction was validated by co-immunoprecipitation (Co-IP). The in vivo effects of DHRS9 knockdown were examined in a subcutaneous xenograft tumor model of nude mice.
resultsBioinformatic analysis showed that elevated DHRS9 expression correlated with reduced overall survival in ovarian cancer patients. Silencing DHRS9 attenuated cell growth, migration, and invasion, whereas promoting apoptotic activity. In contrast, DHRS9 overexpression enhanced oncogenic behaviors and suppressed apoptosis. Mass spectrometry and Co-IP analyses confirmed SQSTM1 as an interacting partner of DHRS9, and knockdown of DHRS9 decreased SQSTM1 protein levels in vivo and in vitro, while its overexpression increased SQSTM1 levels. Moreover, functional studies demonstrated that SQSTM1 knockdown reduced ovarian cell growth, migration, and invasion. Xenograft experiments further demonstrated that DHRS9 knockdown resulted in decreased tumor volume.
conclusionDHRS9 promotes ovarian cancer proliferation, migration, and invasion, and inhibits apoptosis through its interaction with SQSTM1. These findings indicate that DHRS9 may serve as a potential prognostic indicator and therapeutic candidate in ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.